Forendo Pharma Oy has presented aldo-keto reductase family 1 member C3 (AKR1C3) and/or prostaglandin F2-α synthase inhibitors reported to be useful for the treatment of acne, cancer, alopecia, obesity, chronic obstructive pulmonary disease, dysmenorrhea, endometriosis and polycystic ovary syndrome, among others.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) ligand binding moiety covalently bound to a bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety through a linker.
Genescience Pharmaceuticals Co. Ltd. has divulged indoline-containing spiro derivatives acting as growth hormone secretagogue receptor (GHSR) agonists reported to be useful for the treatment of growth hormone deficiency.
Bionova Pharmaceuticals Ltd. has identified heteroaromatic carboxamide compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of asthma, cancer, graft-vs.-host disease, inflammatory bowel disease, psoriasis, thrombotic thrombocytopenic purpura, rheumatoid arthritis and autoimmune thyroiditis, among others.
Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have identified heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Constellation Pharmaceuticals Inc. has described three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.
Janssen Pharmaceutica NV has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of osteoarthritis, cancer, nonalcoholic steatohepatitis (NASH), skin lesion, sarcoidosis, as well as cardiovascular, metabolic and Alzheimer's diseases, among others.
Ocean University of China has identified novel benzotropone derivatives acting as phosphodiesterase 4 (PDE4) and/or cAMP and cAMP-inhibited cGMP 3ʹ,5ʹ-cyclic phosphodiesterase 10A (PDE10A) inhibitors reported to be useful for the treatment of allergy, inflammatory, neurological and cardiovascular diseases.
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. and Mabwell (Shanghai) Bioscience Co. Ltd. have synthesized antibody-drug conjugates (ADCs) consisting of antibodies targeting nectin-4 covalently linked to cytotoxic drugs through a linker reported to be useful for treatment of cancer.
RSS
